Safety, Efficacy of an Accelerated Regimen of Low-Dose Recombinant Tissue-Type Plasminogen Activator for Reperfusion Therapy of Acute Pulmonary Embolism

Bui Hai Hoang, MD, PhD1,2, Phuc Giang Do, MD, MSc1, Lac Duy Le, MD3, Thao Thi Huong Bui, Pharmacist, MSc2, Thinh Nghia Bui, MD, MSc3, Quan Minh Nguyen, MD, PhD3, Duong Hoang To, MD, MSc2, Anh Dat Nguyen, MD, PhD2, Michael M. Dinh, MD, PhD4, Samuel Z. Goldhaber, MD, PhD5, Richard Day6, and Hieu Lan Nguyen, MD, PhD1,2

Abstract
Controversy persists regarding the safety and efficacy of an accelerated low-dose recombinant tissue-type plasminogen activator (rt-PA) regimen for reperfusion therapy in acute pulmonary embolism. This study describes the outcomes of an accelerated low-dose rt-PA regimen for the treatment of acute pulmonary embolism in Vietnamese patients. This was a case series from October 2014 to October 2020 from 9 hospitals across Vietnam. Patients presenting with acute pulmonary embolism with high to intermediate mortality risk were administered alteplase 0.6 mg per kilogram (maximum of 50 mg) over 15 min. The main outcomes were the proportion who survived to hospital discharge and at 3 months as well as in-hospital hemorrhage (major and minor according to International Society of Thrombosis and Hemorrhage definitions). A total of 80 patients were enrolled: 48 (60%) with high risk for mortality and 32 patients (40%) with intermediate risk for mortality. A total of 7 (8.8%) died in hospital. All deaths occurred in the high-risk mortality group. The 73 patients who were discharged alive remained alive at 3 months follow up. During hospitalization, 1 patient (1.3%) suffered major bleeding, and 7 (8.8%) had minor bleeding. An accelerated thrombolytic regimen with alteplase 0.6 mg/kg (maximum of 50 mg) over 15 min for acute pulmonary embolism appeared be effective and safe in a case series of Vietnamese patients.

Keywords
acute pulmonary embolism, low dose rt-PA, alteplase, intermediate risk mortality, high-risk mortality, Vietnam

Date received: 7 June 2021; accepted: 19 July 2021.

Introduction
Thrombolytic therapy is an established treatment for patients with massive acute pulmonary embolism (PE) and evidence of hemodynamic or cardiac compromise. Thrombolysis reduces the embolic burden and improves cardiorespiratory function.1-5 The US Food and Drug Administration (FDA) approved a fixed-full-dose regimen of 100 mg of recombinant human tissue-type plasminogen activator (rt-PA) over 2 h for PE thrombolysis in 1990.1,2

To minimize the risk of catastrophic bleeding associated with thrombolytic agents, several trials have examined the
efficacy and safety of reduced dose rt-PA regimens.\textsuperscript{1,3–5} A retrospective study of patients with PE using thrombolysis (both hemodynamically stable and unstable) demonstrated that patients treated with half-dose alteplase (50 mg) required less vasopressor administration and invasive mechanical ventilation but required escalation of therapy more often than patients treated with full-dose alteplase (rt-PA, 100 mg).\textsuperscript{1} In the moderate pulmonary embolism treated with thrombolysis (MOPETT) trial, 121 patients were randomly assigned to receive heparin alone or the combination of lower dose rt-PA plus heparin. This dose of rt-PA was ≤50\% of the standard dose (100 mg) for patients weighing 50 kg or more and 0.5 mg/kg for those weighing less than 50 kg. Compared with conventional therapy, this lower dose regimen of rt-PA plus heparin resulted at 28 months in lower pulmonary artery systolic pressure (50 ± 6 mm Hg vs 51 ± 7 mm Hg on admission; 43 ± 6 mm Hg vs 28 ± 7 mm Hg at 28 months).\textsuperscript{2,5}

Another regimen proposed is bolus or accelerated-dose with 0.6 mg of rt-PA per kg body weight (maximum of 50 mg) over 15 min delivered intravenously.\textsuperscript{2} In a direct comparison study, no significant differences were detected between the bolus rt-PA and 2-h rt-PA infusion with respect to bleeding complications, adverse clinical events, or imaging studies.\textsuperscript{5} There was less fibrinogenolysis with the bolus dosing regimen.\textsuperscript{7} Some clinical cases had been reported with successful outcomes using this regimen for PE patients with cardiac arrest.\textsuperscript{1,8}

Therefore, the European Society of Cardiology recommended 2 regimens: full-dose and accelerated-dose rt-PA.\textsuperscript{2} However, the comparison of the 2 regimens of alteplase for efficacy and safety requires further study. Wang et al\textsuperscript{10} reported a multicenter randomized controlled trial from China in 118 patients that found similar efficacy between half-dose and full-dose thrombolysis with reduced major bleeding rate in the subgroup of older patients. The aim of this study was to examine the outcomes from using the accelerated regimen with low-dose rt-PA for treatment of acute pulmonary embolism in a multicenter observational study in Vietnam.

### Materials and Methods

#### Study Design and Participants

This was a cohort study.

This research was carried out from October 2014 to October 2020 in 9 major Vietnam hospitals: Hanoi Medical University Hospital, Bach Mai Hospital, Thu Duc District Hospital, Saint Paul Hospital, Hanoi Heart Hospital, Ninh Binh Provincial General Hospital, Phu Tho Provincial General Hospital, Ha Nam Provincial General Hospital and 103 Military Hospital.

- **Inclusion criteria:** All patients aged 18 years and older, who presented with acute pulmonary embolism confirmed by computer tomography pulmonary angiogram (CTPA) and symptom onset within the previous 14 days were eligible. Additionally, patients had to manifest (1) shock/persistent hypotension, and (2) be at risk of at least intermediate-high risk of mortality (Table 1)

| Table 1. Indications for Pulmonary Reperfusion with Thrombolysis. |
|-----------------------------------------------|
| 1. Patients at high risk of mortality from PE (PE with shock or hypotension) |
| • Systolic blood pressure <90 millimeters of mercury (mm Hg) and/or 60 mm Hg diastolic blood pressure (without inotropic or vasoactive drug), need for vasopressors or a decrease in the systolic blood pressure by ≥ 40 mm Hg from baseline. |
| • Hypotension lasting 15 min or longer despite resuscitation not caused by a new-onset arrhythmia, hypovolemia, or septic shock. |
| 2. Patients in intermediate–high risk PE |
| • Patients without shock or hypotension |
| • Simplified Pulmonary Embolism Severity Index (sPESI) ≥ 1 |
| • Evidence of right heart dysfunction: |
| - Transthoracic echocardiography: Enlarged right ventricle on parasternal long axis view or right ventricle/left ventricle ratio ≥ 0.9; pulmonary arterial hypertension (peak systolic gradient at the tricuspid valve > 30 mm Hg), decreased tricuspid annular plane systolic excursion measured with M-mode (< 16 mm), right heart mobile thrombus detected in right heart cavities. |
| - Marker of myocardial injury (laboratory testing): Elevated cardiac troponin T ≥ 0.1 ng/L (or 14 ng/L for hypersensitive troponin T), elevated natriuretic peptide concentrations in plasma N-terminal (NT)-prohormone BNP > 300 pg/mL. |

- **Exclusion criteria:**
  - Absolute: (1) History of hemorrhagic stroke or stroke of unknown origin, (2) ischaemic stroke in previous 6 months, (3) central nervous system neoplasm, (4) major trauma, surgery, or head injury in previous 3 weeks, (5) bleeding diathesis, and (6) active bleeding.
  - Relative: (7) Transient ischemic attack in previous 6 months, (8) oral anticoagulation, (9) pregnancy or first post-partum week, (10) noncompressible puncture sites, (11) traumatic resuscitation, (12) refractory hypertension (systolic blood pressure > 180 mm Hg), (13) advanced liver disease, (14) infective endocarditis, and (15) active peptic ulcer.
  - Patient or delegates did not give consent to thrombolysis treatment.

All patients received alteplase 0.6 mg per kg of body weight (maximum 50 mg) intravenously over 15 min. Unfractionated heparin (initial bolus 80 IU/kg then 18 IU/kg/hr) was commenced 15 min before, and ceased 15 min after the alteplase administration. An activated partial thromboplastin time (aPTT) ratio from 1.5 to 2.3 times the control value was targeted. Any other medication required was at the discretion of the attending physician. The dosage rate of inotropic or vasoactive drug was maintained constant during the period of hemodynamic measurements. The Vasactive-inotropic Score (VIS) was used to measure the severity level of shock. (VIS = dopamine dose [µg/kg/min] + dobutamine dose [µg/kg/min] + 1.00 x adrenaline dose [µg/kg/min] + 100 x noradrenaline dose [µg/kg/min].)
+ 10 × milrinone dose [µg/kg/min] + 10,000 × vasopressin dose [U/kg/min]).

Treatment with rt-PA was followed by oral anticoagulation as recommended by the European Society of Cardiology for a period of 3 months. Surviving patients were discharged and re-examined after 3 to 4 weeks then followed up by trained hospital staff monthly for 3 months. Reasons for failure to return for follow-up were ascertained where possible. Transthoracic cardiac Doppler ultrasound was performed to evaluate the right heart function before and 1 day after treatment with thrombolysis, at time of hospital discharge and at 3 months follow up by a cardiac ultrasound specialist. CTPA was performed before treatment and taken at the time of discharge to evaluate the severity index score of PE.

The main outcomes of our study were the survival rates at hospital discharge and at 3 months, and in-hospital hemorrhage (major and minor according to International Society on Thrombosis and Haemostasis (ISTH) definitions). Other outcome variables collected prospectively included the duration of mechanical ventilation use, vasopressor use duration, hospital length of stay, right ventricular diameter, the pulmonary artery pressure on cardiac Doppler ultrasound and the severity index score of CTPA.

### Statistical Methods

Continuous variables were described as mean and standard deviation or median and interquartile range (IQR) if variables were not normally distributed. Categorical data were described as percentages. Proportions were compared by using the χ² test or Fisher’s exact test when expected values in any of the cells were below 5. The level for statistical significance was set at P< .05. Data were analyzed with R software version 3.0.1.

### Results

In total, 80 patients were enrolled in this study. There were 55 of 80 (68.8%) female patients. The mean age of patients was 61.6 years ± 18.7 (range 18-95 years). There were 45 of 80 (56.3%) patients who were aged 60 years or older.

There were 48 of 80 (60%) patients at high risk of mortality from their PE and 32 80 patients (40%) at intermediate–high risk of mortality.

Survival to hospital discharge occurred in 73 of 80 (91.3%). All deaths occurred in the high-risk mortality PE group. The details of each death are shown in Table 2. All 73 patients that were discharged were alive 3 months later.

### Clinical Course and Adverse Events

In high-risk mortality PE, 23 of 48 (47.9%) patients manifested shock requiring inotropic or vasoactive agents. The median peak of VIS was 34 (interquartile range [IQR] 20-70) most commonly 3 days post admission (IQR 1-6 days). Invasive ventilation was required in 18 of 48 (37.5%) patients for a median of 4 days (IQR 3-7 days). A total of 7 of these patients (14.6%) had a cardiac arrest; 5 had return of spontaneous circulation and 4 were discharged without neurological abnormalities. No patient had thrombectomy or percutaneous catheter-directed treatment; Tables 3 and 4.
There were 2 of 80 (2.5%) patients who developed chronic thromboembolic pulmonary hypertension diagnosed at 3 months follow up.

Discussion

This is the first multicentered study to report on the experience and outcomes of patients treated with an accelerated low-dose thrombolysis regimen for PE in Vietnam. When implementing fibrinolytic agents for treatment of PE in Vietnam, a low-dose regimen was recommended for a number of reasons. First, a lower risk of bleeding was expected.7,12 Second, Vietnamese have lower body weights compared to populations where the original studies were reported. Third, rt-PA is an imported drug considered expensive relative to the health economic conditions of Vietnam. Therefore, reducing the cost of drug dosing is a relevant consideration. The low-dose regimen has now been implemented widely across Vietnam and was recommended by Vietnam National Heart Association and Vietnam National Association of Emergency, Intensive Care Medicine, and Clinical Toxicology.

The survival and major bleeding rates observed in our study compare favorably with previous reports.5,7,12 The pooled survival rate in those 3 studies where 1 group received low-dose regimen group was 96%, with a major bleeding rate of 4%.

There are several limitations to the study. This was a case series without a control group. In addition, the sample size was small.

In conclusion, the accelerated regimen with injection of alteplase at 0.6 mg per kg of body weight (maximum of 50 mg) over 15 min was shown to be effective and safe in a case series of Vietnamese patients with acute high risk and intermediate risk PE.

Authors’ Contributions

BHH conceived and designed the study. BHH, GPD, DLL, NTB, MQN, DAN, and LHN acquired, analyzed, and interpreted the data. BHH and GPD drafted the manuscript. BHH, VTN, LHN, THTB, NTB, MD, RD, and SZG critically revised the manuscript for important intellectual content. HBH and GPD did the statistical analysis. DLL and GPD provided administrative, technical, or material support.

There were 2 of 80 (2.5%) patients who developed chronic thromboembolic pulmonary hypertension diagnosed at 3 months follow up.

### Table 4. Transthoracic Echocardiography and Computer Tomography Pulmonary Angiogram (CTPA) Before and After Thrombolysis.

| Measure                              | Before thrombolytic therapy | After 1 day | At the time of hospital discharge |
|--------------------------------------|-----------------------------|-------------|----------------------------------|
| Right ventricular size (mm)          | 30.1 ± 3.40                 | 24.4 ± 5.46 | 22.04 ± 1.3                      |
| Pulmonary artery pressure (mm Hg)    | 51.0 ± 11.14                | 35.5 ± 6.94 | 33.45 ± 5.65                     |
| Severity index score on CTPA         | 55.9 ± 13.25                | Not available | 32.5 ± 14.33                     |

where $n$ represents the number of affected pulmonary arteries (there are 20 pulmonary arteries; $1 \leq n \leq 20$ and $d$ is the weighted coefficient of obstruction, where 0 indicates no embolism, 1 partial embolization, and 2 complete embolization. Complete embolization of pulmonary arteries is graded 40 and the severity index equals 100%.10

#### Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

#### Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

#### Ethical Approval

This trial was approved by The Ethics Committees of Thu Duc District Hospital (Declaration No10/BV-HDDD, September 14th, 2014).

#### ORCID iD

Bui Hai Hoang https://orcid.org/0000-0002-4012-9066

#### References

1. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e419S.
2. Konstantinides SV, Torbicki A, Agenelli G, et al. ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35:3033.
3. Sharifi M, Awdisho A, Schroeder B, et al. Retrospective comparison of ultrasound facilitated catheter-directed thrombolysis and systemically administered half-dose thrombolysis in treatment of pulmonary embolism. Vasc Med. 2019;24:103.
4. Kiser TH, Burnham EL, Clark B, et al. Half-Dose versus full-dose alteplase for treatment of pulmonary embolism. Crit Care Med. 2018;46:1617.
5. Wang C, Zhai Z, Yang Y, et al. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest. 2010;137:254.
6. Sharifi M, Bay C, Skrocki L, et al. Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” Trial). Am J Cardiol 2013;111:273.
7. Goldhaber SZ, Agenelli G, Levine MN, et al. Reduced dose bolus alteplase versus conventional alteplase infusion for pulmonary
embolism thrombolysis. An international multicenter randomized trial. *Chest*. 1994;106:718-724.
8. Böttiger BW, Böhrer H, Bach A, et al. Bolus injection of thrombolytic agents during cardiopulmonary resuscitation for massive pulmonary embolism. *Resuscitation*. 1994;28:45-54.
9. Na SJ, Chung CR, Cho YH, et al. Vasoactive inotropic score as a predictor of mortality in adult patients with cardiogenic shock. *Medical Therapy Versus ECMO*. 2019;72(1):40-47.
10. Qanadli SD, El Hajjam M, Vierlillard-Baron A, et al. New CT index to quantify arterial obstruction in pulmonary embolism: comparison with angiographic index and echocardiography. *Am J Roentgenol*. 2001;176:1415-1420.
11. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antithrombotic medicinal products in nonsurgical patients. *J Thromb Haemost*. 2005;3(4):692-694. doi:10.1111/j.1538-7836.2005.01204.x. PMID 15842354.
12. Sors H, Pacouret G, Azarian R, et al. Hemodynamic effects of bolus versus 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. *Chest*. 1994;106:712-717.